JP2001172204A - Method of making and selling examination chemical, installation for making and selling examination chemical, method for feeding examination chemical and supplying system therefor - Google Patents

Abstract

PROBLEM TO BE SOLVED: To effectively utilize the nuclides of a short half-life for the medical inspection in the positron emission type computer tomography(CT) and the system therefor. SOLUTION: The nuclide (18F) 13 is produced by means of the cyclotron 2 in the hospital facilities 1. Additionally, inspection devices 5 and the synthesis devices 3, 4 are installed in combination in the hospital facilities. The nuclide 13 is used as a starting material for synthesizing the chemical for the positron emission type CT in the synthesis device 4 and the chemical is transferred to the inspection devices 5. The excessive nuclides 13 may be supplied to other hospital facilities 14, 25. Chemical-synthesizing devices 26, 27 are arranged in the hospital facilities 14, 25 the chemicals for the positron emission type CT are synthesized by means of individual synthesizers. The process time for these chemicals are calculated based on the half-life period of these nuclides and controlled and are served for the positron emission type CT in individual hospital facilities.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an apparatus for producing a drug used for a positron emission CT examination and an inspection method using the drug.
In particular, the present invention relates to a positron emission CT examination method for examining cancer or the like using a drug that uses a radionuclide having a short half-life as a raw material, and to various facilities such as an examination car used for the examination.

[0002]

2. Description of the Related Art Currently, SPECT is used as a means of treating cancer.
(Single-photon emission CT) is known. In this method, a test chemical is prepared using nuclides (99MO, 1311, etc.) manufactured in a nuclear reactor and nuclides (1231, 201T1, etc.) obtained in an accelerator, and these are used for inspection.
The half-life of these nuclides was relatively long, 2-3 days.

[0003] By the way, from the viewpoint of further improving the measurement performance, PET (positron emission type C) is used instead of SPECT.
T) Inspection is being adopted. The nuclide used as a drug material for positron emission CT, that is, PET, is produced by an accelerator, but has a very short half-life compared to SPECT, and a considerable amount of nuclides must be produced to secure the amount used for inspection. However, it must be used promptly in consideration of the half-life.

[0004] The circumstances of the adoption of PET are described, for example, in "PET Communication 1998 WINTER" issued by Institute of Advanced Medical Technology.
No. 25 ", pp. 15-17.

Japanese Patent Application Laid-Open No. 60-185730 discloses a method for synthesizing a radioactive compound, in which an intermediate of a target radioactive compound is sealed and prepared in a reaction vessel in advance for every fixed amount, and the reaction vessel is prepared at the time of synthesis. Attached to the radioactive compound synthesizer,
A method for synthesizing a radioactive compound using a short-lived nuclide characterized by reaction synthesis is described.

[0006]

The problem of the half-life will be described with reference to nuclide 18F (fluorine having an atomic weight of 18: sometimes referred to as fluorine 18).

[0007] In the case of fluorine 18, the half-life is 110 minutes (about 2 hours).
The amount of fluorine 18 as a positron-emitting nuclide contained in the drug decreases in accordance with the time required for synthesis and transport. For example, 1/2 hour in 2 hours, (1/2) ⁴ = 1/16 in 8 hours
To decrease. After 24 hours, (1/2) ¹² = 1/40
96, which is the original 0.02%. The amount of fluorine 18 required for one human administration depends on the weight of the human body, but is, for example, 370 MBq. Over time, the amount of the drug decreases as described above, so that it is necessary to inject or concentrate a larger amount of the drug. Usually, 10 cc is administered. However, in order to administer 10 mCi, 160 cc is injected for a drug that has passed 8 hours, which increases the burden on the patient. Therefore, after drug synthesis, it is essential to minimize the time until administration to the human body in order to use the drug effectively. Since the accelerator facility is expensive, an accelerator cannot be installed at each medical facility, so that there is no choice but to take means of transportation and delivery, and there is a problem that it takes time at a remote medical facility. Fluorine 1
Carbon 11 shorter than half life of 8 (half life 20 minutes), nitrogen 1
In the case of 3 (half-life 10 minutes) and oxygen 15 (half-life 2 minutes), the above problem becomes more serious.

In view of the above, it is an object of the present invention to provide a method and apparatus for producing a test drug, and a method and system for supplying the test drug, which can effectively utilize nuclides having a short half-life. .

[0009]

SUMMARY OF THE INVENTION The present invention relates to a method for producing a nuclide, a method for producing a medicine, and a method for providing a medicine using a radionuclide having a short half-life as a raw material component to an inspection facility or a hospital facility. It is characterized by a positron emission type CT inspection method that takes into account the administration to the patient, etc., and further includes various equipment used for this inspection (including a medical checkup car) and a method or equipment for manufacturing nuclides or drugs (including a car equipped with a manufacturing equipment). ).

In the present invention and the present specification, the following definitions are used.

Hospital facility: In the present application, this is a concept based on medical law including a hospital, a clinic, a midwife, and the like. However, the “medical bed group”, the “care facility for the aged” and the “midwife” are not covered by the present invention. According to the medical law, a "hospital"
A place where a doctor or dentist performs medical or dental work for the public or a specified number of people (Article 1), and has a housing facility for 20 or more patients. Hospitals must be organized and operated with the primary purpose of providing the patient with the convenience of receiving scientific and proper medical care. "Clinic" means a place where a doctor or dentist performs medical or dental work for the public or a specified number of people, and does not have a patient accommodation facility or has a facility with 19 or fewer patients Say.

In the present application, the inspection facility is a facility capable of performing a screening using a positron-emitting drug at the time of a screening, and although there is a conceptual overlap with a hospital facility, it is limited to a so-called testing.
Means a facility that does not engage in treatment.

A nuclide is a radioisotope. The radioisotopes used for positron emission CT, ie, PET, are mainly composed of carbon 11 (hereinafter, described as 11C), nitrogen 13 (hereinafter, described as 13N), oxygen 15 (hereinafter, described as 15O), and Fluorine 18 (hereinafter, 18F
There is).

When the nuclide is 18F, it is desirable that the period from the synthesis of the nuclide to the start of use of the test be within 8 hours in consideration of the half-life and the amount used. Half-life 2 hours 1
In 8F, after 8 hours, the nuclide amount becomes (1/2) ⁴ = 1 /
It is reduced to 16. When using the drug, it is desirable to increase the dose by 16 times. In other words, 160 cc of a drug that was originally intended to be administered at about 10 cc will be administered. The lower limit of the time range is set to the minimum required time from the start of production to the start of use (administration), for example, one minute that would be required for online transportation. In the above, the amount of radioactivity at the time of administration, considering that radioactivity is attenuated in the time from synthesis to administration, by increasing the amount of the synthesized drug, the amount of radioactivity suitable for the human body to be administered Is to adjust.

The amount of the nuclide synthesized for the test (the amount of the nuclide contained in the synthesis) is preferably, for example, at least four times the weight of the nuclide occupied by the drug at the time of the test. If the time from synthesis to use is 4 hours, (1 /
2) ² = 1/4, and if the nuclide amount is four times that of the amount used during synthesis, an appropriate amount can be administered at the time of use. Since the dose is determined by the amount of radioactivity, in the above example, the amount of radioactivity of the synthesized drug is set high in advance,
Considering that radioactivity is attenuated during the time from synthesis to administration, the radioactivity is diluted and adjusted with physiological saline so that about 370 MBq, which is an appropriate amount depending on body weight, is administered. For example, a drug after synthesis (200 MBq to 1.3 G
(About Bq / ml) is 740 MBq / ml.
5 ml has the amount of radioactivity for one human body. In the example above,
Even if the amount of radioactivity is reduced to 1/16, and therefore, even if the dose is increased 16 times, 0.5 × 16 = 8 ml, which is not a large dose.

With regard to the drug, this should be taken into account in radiation management. That is, after administration, the test is carried out after waiting about 20 minutes to 1 hour until the drug reaches the whole body. The inspection time is preferably about 20 to 40 minutes. still,
After the examination, the subject should not leave the facility until the radioactivity has been sufficiently attenuated. Excreta during that time should also be managed.

As described above, the entire process from nuclide generation to drug disposal is controlled based on the time required for each process, taking into account the decay of the nuclide based on its half-life, Provides the optimal amount of radioactivity for human administration.

Incidentally, an example of the drug includes NaF.
This can be obtained simply by adding sodium chloride to 18F, so that the preparation method is simple, and the drug is effective against bone cancer. In this case, it is preferable to supply the liquid in the form of a liquid contained in a container.

According to the present invention, in a method for producing a positron-emitting drug, an order is attached to a positron-emitting drug, the date and time of use, the place of use, the amount of use, and the target nuclide, and the generation of the nuclide is started. A positron emission type that calculates a process time including a time, a transport time of the nuclide, a start time of drug synthesis by the nuclide, and a transport time of the drug based on a half-life of the nuclide, and creates a time schedule based on the calculated half-life. Provided is a method for producing a medicament.

According to the present invention, in a method for producing a positron-emitting drug, a process time including a nuclide generation start time and a drug synthesis start time by the nuclide is calculated based on the half-life of the nuclide, and the preparation status for screening is calculated. To provide a method for producing a positron-emitting drug for instructing the generation of the nuclide.

According to the present invention, in a method for producing a positron-emitting drug, an order is attached to a positron-emitting drug, the date and time of use, the place of use, the amount of use, and the target nuclide. The process time including the time, the transport time of the nuclide, the start time of drug synthesis by the nuclide, and the transport time of the drug is calculated based on the half-life of the nuclide. The present invention provides a method for producing a positron emitting drug.

The present invention further provides the order, the nuclide generation start time, the nuclide transport time, the drug synthesis start time by the nuclide,
Display nuclear process time on the screen, including drug transport time,
The present invention also provides a method for producing a positron-emitting drug in which the preparation status of a medical examination is also displayed on the same screen, and the nuclide generation instruction is issued through the screen.

[0023] The present invention provides a method of manufacturing a positron emission agents, the half-life of the nuclide _{t h,} the decay constants _t d (= _{l n}
2 / th _h ), N is the amount of nuclide used for inspection, No is the amount of nuclide generated by the particle generator (cyclotron), t _{1 is} the nuclide purification time, t _{2 is} the nuclide transport time, and n is the nuclide. N = No · S exp (−t _d (t ₁ + t ₂ + t ₃ + t ₄ )), where t _{3 is} the manufacturing time of the drug, t ₄ is the time required for testing the drug, and S is the yield of drug manufacturing. The present invention provides a method for producing a positron-emitting drug for producing a nuclide based on the half-life of the nuclide such that

According to the present invention, in the method of supplying a positron-emitting drug, an order is attached to the positron-emitting drug, the date and time of use, the place of use, the amount of use, and the target nuclide, and the generation of the nuclide is started. The process time including the time, the transport time of the nuclide, the start time of drug synthesis by the nuclide, and the transport time of the drug is calculated based on the half-life of the nuclide, and based on the calculated half-life, the synthesis of the drug and the supply route of the drug The present invention provides a method for supplying a positron-emitting drug which creates a time schedule for the supply of a drug containing:

The present invention further provides a method of supplying a positron-emitting drug which stores clinical data as a result of using the supplied drug in association with the nuclide.

According to the present invention, in supplying a nuclide for a positron-emitting drug, the nuclide receives an order based on at least four types of information on the purpose of use, the place of use, the amount of use, and the target nuclide. The present invention provides a method for supplying a positron-emitting drug nuclide for supplying a nuclide generated based on the half-life to a purchaser.

The present invention further provides a method for supplying a positron-emitting drug nuclide in which the ordering side is a hospital facility or a testing facility.

The present invention further provides a method of supplying a positron-emitting drug nuclide via a management agency for managing radioactive materials in the process of ordering and / or supplying.

According to the present invention, in supplying a nuclide for a positron-emitting drug, the nuclide receives an order based on at least four pieces of information on the purpose of use, place of use, amount of use, and target nuclide, and receives the information and the nuclide. The nuclide generated based on the half-life of the nuclide is supplied to the ordering hospital facility or testing facility, and the transport time is calculated from the transport route and transport means between the nuclide generating facility and the ordering hospital facility or testing facility. A method for supplying a nuclide for a positron-emitting drug, which starts nuclide generation and supplies an amount of nuclide corresponding to the order quantity of the ordering facility, is provided.

The present invention relates to a positron-emitting drug manufacturing and processing apparatus, which receives at least four pieces of information about a positron-emitting drug, such as date and time of use, place of use, amount of use, and a target nuclide, and displays a screen display device, A process of calculating a process time including a production start time, a transport time of the nuclide, a drug synthesis start time by the nuclide, and a transport time of the drug based on a half-life of the nuclide, and creating a time schedule based on the half-life. And a device for manufacturing and processing a positron-emitting drug.

According to the present invention, there is provided a sales processing device for a positron-emitting drug, comprising: a screen display device for displaying, on a screen, an order containing at least four pieces of information on a positron-emitting drug, such as date and time of use, place of use, amount of use and target nuclide. A statistical processing device for inputting / statistically inputting a shipping amount of a drug synthesized using a nuclide manufactured based on the half-life of the nuclide, and a billing processing device for charging the drug shipping amount based on the statistics And a sales processing device for a positron-emitting drug having the following.

According to the present invention, in the sales processing apparatus for a positron-emitting drug, an order screen is received for each order, the order including at least four pieces of information on the date and time of use, the place of use, the amount of use, and the target drug. A screen display device for displaying, a statistical processing device for statistically calculating the shipping amount of a drug synthesized using the nuclide manufactured based on the half-life of the nuclide for each order, and for each orderer based on the statistics. Provided is a sales processing device for a positron-emitting drug, which has a billing device for billing a drug delivery amount.

According to the present invention, in a positron-emitting drug manufacturing and processing apparatus, at least four pieces of information on a positron-emitting drug, such as date and time of use, place of use, amount of use, and target nuclide, are received and displayed on a screen, and preparation for medical examination is performed. A screen display device for displaying the status on a screen, and a process time including a generation start time of the nuclide, a transportation time of the nuclide, a start time of drug synthesis by the nuclide, and a transportation time of the drug are calculated based on a half-life of the nuclide. And create a time schedule based on it,
And a processing device for instructing the generation of the nuclide with reference to the preparation status of the medical examination.

According to the present invention, in a system for manufacturing a positron-emitting drug, at least four pieces of information on a positron-emitting drug, such as date and time of use, place of use, amount of use, and target nuclide, are received and displayed on a screen, and preparation for examination is performed. And a process time including a generation start time of the nuclide, a transport time of the nuclide, a start time of drug synthesis by the nuclide, and a transport time of the drug, based on the half-life of the nuclide. , Create a time schedule based on that,
A processing device for instructing the generation of the nuclide with reference to the preparation status of the screening, a device for generating a positron-emitting nuclide according to a time schedule, a first transport device for transporting the nuclide, and using the nuclide as a raw material Provided is a system for producing a positron-emitting drug, comprising a drug synthesizing device for synthesizing a drug, a second transport device for transporting the drug, and a transmission system for transmitting a confirmation signal of the drug delivery to the processing device. .

According to the present invention, there is provided a tumor examination processing apparatus for examining the presence or absence of a tumor using a nuclide, a reception processing apparatus for registering an order of an examination drug synthesized from the nuclide and an examination time, and relies on a half-life of the nuclide. Drug production instruction device for producing a nuclide and instructing when to synthesize a positron emission-type test agent from the nuclide, responding to the order of the synthesized test agent, and performing delivery and billing for the test agent Provided is a tumor inspection processing device including a billing processing device.

According to the present invention, there is provided a tumor examination processing apparatus for examining the presence or absence of a tumor by using a nuclide, a storage device for storing a tumor examiner, examination items of the tumor for the examiner, a name of the examiner, and a status of preparation for examination. Provided is a tumor inspection processing device provided with a drug production instruction device for displaying and instructing when to produce a nuclide and synthesize a test drug from the nuclide depending on the half-life of the nuclide.

According to the present invention, there is provided a tumor examination processing apparatus for examining the presence or absence of a tumor using a nuclide, in which the examiner and the examination items of the tumor are stored for the examiner, and when a test agent is synthesized from the nuclide. A storage device for storing the time required from the synthesis to administration of the test agent, a screen display of the name of the examiner and the state of preparation for the examination, and displaying the time, depending on the half-life of the nuclide, Provided is a tumor inspection processing device including a drug production instruction device for producing and instructing a timing of synthesizing a test drug from a nuclide.

According to the present invention, in a tumor examination processing apparatus for examining the presence or absence of a tumor using a nuclide, a positron emission type CT examination facility is provided in an examination car, and the examination person and the examination items of the tumor for the examination person are stored. A storage device, a synthesis instruction device for instructing the synthesis of a positron emission-type test agent from a nuclide depending on the half-life of the nuclide, and a test using the test agent administered to the examiner in connection with the test agent Provided is a tumor test processing device provided with a registration device for registering a result.

According to the present invention, there is provided a tumor inspection processing apparatus for performing an examination for the presence or absence of a tumor using a nuclide, a synthesis instructing apparatus for displaying an examination preparation state of a examiner on a screen and instructing to synthesize an examination drug from the nuclide. Provided is a use device for putting a synthesized test drug on a transport route for use in a test facility, and a tumor test processing device provided with a storage device for storing clinical data as a result of use in association with a nuclide.

[0040]

DETAILED DESCRIPTION OF THE INVENTION Embodiment of Positron Emission CT Inspection Method; Examples of the embodiment of the positron emission CT inspection method in the present invention are as follows: (1) A nuclide is introduced as a drug substance for inspection from outside the inspection facility, and is introduced into the inspection facility. (2) a method of synthesizing the drug every time of the test, and providing the test in the test facility after the synthesis; (2) synthesizing a test drug using nuclide as a raw material in the hospital facility each time of the test, and combining the synthetic drug with the test (3) Positron emission type C
A nuclide is manufactured inside an inspection facility or a hospital facility equipped with a T inspection facility, and a test chemical using this nuclide as a raw material is synthesized and provided for inspection, and the nuclide is transported outside the inspection facility or the hospital facility. , A method used as a raw material of a test drug to be used in another test facility or hospital facility,
(4) A nuclide is manufactured in an inspection facility or a hospital facility equipped with a positron emission CT inspection facility, a test chemical using this nuclide as a raw material is synthesized and provided for inspection, and the nuclide is subjected to the inspection facility or the inspection facility. It is transported outside the hospital facility and used for other testing facilities or hospital facilities, and at the same time, new drugs are loaded on the transport route and used for other testing facilities or hospital facilities to acquire clinical data. (5) Nuclides are manufactured at a nuclide synthesis facility outside the laboratory or hospital facility, and the nuclides are transported to the laboratory or hospital facility for use in testing, and the new drug is placed on the transport route. To obtain clinical data for use at each laboratory or hospital facility, and to collect this data,
(6) Positron emission type C outside inspection facilities or hospital facilities
A method for producing a nuclide or a drug for a T test drug, supplying the drug to a predetermined facility, introducing a test car equipped with a positron emission type CT test facility into the predetermined facility, and performing a test in the test car. , Etc.

Here, "every test" has the following significance. The inspection takes some time, for example, about 2 hours. Ideally, a drug synthesized immediately before the test is produced, but in reality, it takes time to move (transport).
For example, 30 minutes before, (1/2) ^0.5 = 0.84, and the nuclide amount attenuates by about 10%. In view of the attenuation, it is sufficient that the drug contains a large amount of nuclide. When a plurality of inspection devices are inspected in parallel by one inspection device for four persons a day, if the inspection time is, for example, two hours, the inspection time is combined and supplied every two hours according to the inspection time. Can be considered. Since the number of persons who can start an examination in parallel at one time is determined by the number of examinations, for example, when there are five examination apparatuses in a hospital, it is preferable to combine them so that five persons can be supplied every two hours. Note that it is ideal to notify the test applicant to the test time and perform the test several times at a time.

B. Various Vehicles: The medical checkup car according to the present invention is a vehicle equipped with an apparatus for synthesizing a test chemical using nuclides as a raw material and a positron emission CT apparatus for testing using the chemical. This car can be inspected using a test chemical that uses nuclides as a raw material, can be inspected with the above-mentioned chemicals in the car, or can be moved to a hospital or inspection facility for inspection. Nuclide used, for example,
Preferably, 18F is produced by an accelerator.

In the drug delivery vehicle for positron emission CT examination according to the present invention, a synthesis device for manufacturing a test drug using nuclides as a raw material is mounted in the vehicle, and the synthetic drug is supplied to an inspection facility or a hospital facility. It is preferable that an accelerator for producing the nuclides is also provided.

The nuclide production vehicle according to the present invention has an on-vehicle equipment for producing a nuclide used as a raw material for a positron emission type CT examination drug. This manufacturing apparatus preferably includes an accelerator.

C. Other handling precautions: Radioisotopes with a radioisotope concentration of more than 74 becquerels per gram must be transported as radioactive transport.
For example, an L-type transport (liquid ≦ A2 ×
10 ^-4 ). A type transported product (≦ A2) is a type of transported product in which the number of radioisotopes and the like to be stored is not more than a certain amount. Type A gives the transport container the strength to withstand transport. BM or BU type transported goods (> A2) are transported goods in which the quantity of radioisotopes and the like to be stored exceeds a certain amount. The BM or BU type requires a strong transport container that can withstand severe accidents.

The A2 values of 18F, 11C and 13N are all 0.5 TBq. Therefore, 0.5 TBq
Transport below (13.5 Ci) is preferred.

(Examples) Hereinafter, examples of the present invention will be described.
This will be described with reference to the drawings.

FIG. 1 is a system configuration diagram according to the first embodiment. A cyclotron 2 is provided inside the hospital facility 1, and the cyclotron 2 provides one of nuclides 18
F13 is manufactured. Further, a plurality of inspection devices 5 are provided inside the hospital facility 1, and synthesizing devices 3 and 4 are also provided. Nuclide 13 produced by cyclotron 2
Arrives at the synthesizing device 4 via the route 10, where a drug for positron emission CT examination is synthesized, and this drug reaches each testing device 5 via the route 7. The nuclide 13 supplied from the cyclotron 2 to the synthesizing apparatus 4 is manufactured at least at each inspection, but in this example, the surplus nuclide is further added to other hospital facilities 1.
4, 25 (a plurality of possible locations) are supplied through the route 12. Each of the hospital facilities 14 and 25 also has a drug synthesis device 26,
27, each of which synthesizes a positron-emission-type CT examination drug by each of the synthesizing devices, and converts the positron-emission-type C in each facility.
It is designed for T inspection. As described above, in this example, the examination service 11 is formed by a plurality of hospital facilities.

FIG. 1 also shows a route 15 indicated by a broken line from the synthesizing apparatus 3 to each of the hospital facilities 14 and 25. These routes 15 are routes for supplying a new drug 16 for a clinical test, for example, a cyclotron. The nuclide produced in 2 and the like is provided to the hospital facility 3 via the route 6 to synthesize a new drug, and this is provided to the respective hospital facilities 14 and 25 outside the hospital facility 1 as the manufacturing facility to provide a clinical medicine. It is a mechanism to obtain data. The route for providing the new drug for acquiring clinical data overlaps with the route for providing the nuclide 13 to improve the efficiency of the transport route.

The mechanism disclosed on the right side of FIG. 1 is a new drug joint development route 1 between a university or research institution 17 and a nuclide manufacturing facility 19.
8 is assumed. A cyclotron 20 is provided inside the nuclide production facility 19, and as in the case of the cyclotron 2, a radionuclide 13 is produced, and a nuclide 1 is produced.
3 is supplied to the hospital facility (s) via the route 31 and is provided to the synthesizing device 30 in the hospital facility 28 to synthesize a positron emission type CT examination agent to perform positron emission type CT examination in each facility. To serve. The route 23 indicated by the broken line is a route for providing the new drug 24, and the route for providing the new drug for acquiring clinical data overlaps with the route for providing the nuclide 13 to improve the efficiency of the transport route. The synthesizing apparatus 22 in the nuclide manufacturing facility 19 is an apparatus for manufacturing the new drug from a nuclide as a raw material. The nuclide 13 is supplied from the cyclotron 20 to the apparatus by a route 32.

In the present application, a drug that has been developed in the future and is supposed to obtain drug manufacturing approval from the Ministry of Health and Welfare is called a new drug. It is not limited to 18F-FDG as a cancer screening, and new drugs are also targeted. A solid line indicates a drug supply route, and a broken line indicates that a hospital is requested to acquire clinical trial data instead of supplying the drug for a fee.

The route 33 is used for synthesizing the nuclide 13 with the synthesizer 21.
Although this synthesizer 21 does not have an inspection-side route, this is a device for confirming whether or not the synthesizer 21 can obtain a predetermined drug from a nuclide. Does not provide for inspection.

Although not shown in the drawing, each of the examination devices 5 is also provided in each of the hospital facilities 14, 25, and 28, and includes a camera, an examination table for the examinee, and the like.

In this embodiment, the nuclide synthesizing apparatus uses the cyclotrons 2 and 20, but other accelerators or particle generators other than the accelerator may be used. For example, linear accelerators are promising alternatives to cyclotrons.

Hospital facility 1 or / and other hospital facilities 1
From the terminal devices 71 and 72 provided in the medical equipments 4 and 25, the medicine receiving / processing device (CPU) 73 of the hospital facility 1 receives 1) a place of use, 2) a target medicine name, 3) a target medicine quantity, and 4) a test start. Time, 5) The inspection item is input and accepted via the communication means 74 (including the Internet). 2) The target nuclide name may be used instead of the target drug name, and 3) the target nuclide amount may be used instead of the target drug quantity. The drug receiving / processing device 73 calculates the process time including the nuclide generation start time, the transport time of the nuclide, the drug synthesis start time by the nuclide, and the drug transport time based on the half-life of the nuclide. Based on this, a time schedule and a delivery route for production and delivery are created. Therefore, it will be understood that the transport time of the nuclide and the transport time of the drug include the transport time in the hospital facility 1 as well as the transport time to the other hospital facilities 14 and 25. .

As described later, the medicine is synthesized, and the medicine is received from the medicine receiving / processing device 73 in accordance with 1) delivery destination, 2).
Delivery date, time, 3) drug name, 4) drug quantity, 5) delivery mode (e.g., container storage for each individual examiner) are output. Drugs synthesized based on this output are delivered by destination.
The output is sent to the terminal devices 71 and 72 via the communication means 75.
And the delivery status is reported. 3) The nuclide name may be used instead of the drug name, and 4) the nuclide quantity may be used instead of the drug quantity.

One embodiment of the present invention is to receive an order with at least four pieces of information on the date and time of use, the place of use, the amount of use, and the target nuclide with respect to the positron-emitting drug, and to start the generation of the nuclide and the generation of the nuclide. Calculating the time, the transport route and the transport time of the nuclide, the process time such as the drug synthesis start time and the synthesis time, the drug transport time and the drug administration time, based on the half-life of the target nuclide; A system for creating a time management schedule based on the yields in each process such as the yield of a positron-emitting radionuclide in accordance with the time management schedule, Means for transporting, an apparatus for synthesizing a drug using the nuclide as a raw material, an apparatus installed near a facility using the drug, means for transporting the drug, and a status information signal in each process such as a confirmation signal for the drug delivery To Constituted by the manufacturing system of positron emission agents consisting of a system for transmitting a time management schedule.

The outline of the drug synthesis and test employed in this example will be described with reference to FIGS. First, cyclotron 2, 20
To produce a nuclide and supply it to the drug synthesizing apparatus 4, for example, synthesize a test drug each time the test is performed, and
The inspection is performed using the T camera system 5, and the image diagnosis is performed by the image diagnosis device 34.

Next, the principle of generation of fluorine 18 ( ¹⁸ F) 13 by a particle generator 35 such as a cyclotron will be specifically described. First, accelerated protons (p) are incident on oxygen 18 ( ¹⁸ O) (reference numeral 37) to obtain water 36 containing oxygen 18, and further, a nuclear reaction ¹⁸ for generating fluorine 18 ( ¹⁸ F) and neutrons (n). O (p, n) ¹⁸ F generates fluorine 18 (reference numeral 13). Oxygen 18 ⁽¹⁸ O) is natural abundance of 0.2%
Therefore, when it is desired to increase the generation amount of fluorine 18, it is necessary to increase the concentration of oxygen 18, that is, use an enriched one. To this, protons accelerated to about 10 MeV by a particle generator such as an accelerator are applied. The synthesizing devices 4 and 21 are as described above.

Next, the principle of using a test chemical synthesized using this nuclide for a test will be described with reference to FIG. This example method is called a gamma ray measurement method. First, an internal drug aqueous solution is injected (administered) into a subject using a nuclide as a synthesis raw material. The administered drug moves through the body. Fluorine 18 ( ¹⁸ F) contained in this drug emits a positron (e ⁺ ).
The positron collides with the electron (e ⁻ ) in the substance and disappears,
Γ rays 42 and 43 having an energy of 1 keV
Release. The two gamma rays 42 and 43 are 180
Released in the ゜ direction. The two γ-ray detectors 38 and 39
One gamma ray is measured, and the position of the generated gamma ray is identified.
As the γ-ray detectors 38 and 39, for example, a scintillator and a photomultiplier are used. The signals detected by the γ-ray detectors 38 and 39 pass through a coincidence circuit 40, a signal processing circuit 41 such as a spectrum analyzer, and the like, and an image is created by a computer (see the device indicated by reference numeral 34 in FIG. 2). Based on this image, the doctor makes an inspection.

The fact that cancer is present means that, for example, FDG (fluorodeoxyglucose) containing fluorine 18 is a kind of glucose, that is, sugar, and is collected in places where metabolism is intense, that is, where consumption of sugar is large. Cancer is also a site of high glucose metabolism, where FDG gathers. Thus, by measuring the generated γ-ray and identifying the position, the γ-ray generation position, that is, the position of the cancer can be known.

Next, the synthesis of fluorine 18 will be described as an example of the synthesis of a nuclide as a raw material of a drug. In this example, a fluorine ion method will be described. In the fluorine ion method, the following is performed. Fluorine ions are adsorbed by passing target water containing fluorine ions through an ion exchange resin. Fluorine ions are desorbed with an aqueous potassium carbonate solution and introduced into the reactor as KF. A treatment such as addition of an acetonitrile solution is performed for purification. Distilled water for injection is added to this to make a drug for injection. Note that the size of the synthesizing device is sufficient to be on a table.

By the way, even if it becomes a drug, the radionuclide contained therein is attenuated by the half-life of the radionuclide, so that the amount of radionuclide contained in the drug is reduced. Thus, the lifetime of the manufactured drug will decay at the same rate as the half-life of the radionuclide.

Next, the state of circulation of nuclides (for example, what kind of concentration of an aqueous solution is to be put in which container) will be described. Based on the Radiation Hazard Prevention Law, this substance becomes a type A transported product (a transported product of a specified amount or less), and a lead container is prepared by installing an absorbent under a container containing an aqueous solution, for example, a resin container. , And the lead container is canned together with the spacer and transported in a cardboard box.

As a method for providing a nuclide, for example, 18
There is a method of supplying F by a column (φ1 mm × 50 mm).
Incidentally, the liquid may be supplied in some cases. From the cyclotron targets, come out _{18F-H 2} O, including 18F. By passing this through a plurality of metal columns (φ1 mm × 50 mm) containing an ion exchange resin (also referred to as a filler, which is a solid, usually in the form of particles or powder), only 18F is adsorbed. Remaining 18F-H discharged from the column
₂ O is returned to the cyclotron. This column is supplied to a nearby hospital. When used as a raw material for synthesis in a hospital, 18F adsorbed on the column is desorbed and introduced into a synthesis device. The procedure before the synthesis is intended to be carried out on the cyclotron side. However, since 18F is in the form of HF,
Since the column is corroded, it is better not to use a glass bottle or a vial bottle, for example, a resin container is suitable.

Since the nuclide used in the present invention has a short half-life, it is important to control the subject, the half-life and the amount used (injection amount, drug input amount).

Unless concentrated, a drug which takes a long time to transport and has a reduced amount of fluorine 18 cannot be diagnosed without increasing the dose of the drug and administering a predetermined radioactivity, for example, 370 MBq. At the time of drug administration, the fluorine 18 contained in the drug is calculated backward from the time required for synthesis and transport.
Is measured or measured by a radioactivity detector, and the dose of the drug is controlled so as to be a predetermined radioactivity, for example, 370 MBq. Since the dose is determined by the weight of the patient, the amount of the drug is determined in consideration of the weight.

How to enrich radioisotopes: For example, fluorine 18 emits a positron to become oxygen 18. In order to increase the concentration of fluorine 18 in a unit volume, a chemical property is used as a method of separating from fluorine 18. That is, separation is performed using the difference in the boiling point or the melting point between fluorine and oxygen. The same procedure is used for other radioisotopes.

Next, measures for radiation exposure will be described. About 10
Since protons are accelerated to MeV, fluorine 18
A shield is required to cover the 10 MeV protons up to the generator. For example, in the case of lead, the range of protons in lead is 0.04 cm, so a lead plate several times thicker than that will be installed.

Fluorine 18 emits a positron of 0.6 MeV. Since the range of the positron in lead is 0.02 cm or the like, for example, a container wall or the like containing fluorine 18 serves as a positron shield. For example, it is necessary to provide, for example, a lead plate shielding structure in the production of a drug, in the process of shortening the process, and in a vehicle. The shielding material is not limited to this, and may be concrete, for example, but it is necessary to consider the securing of space because the wall is thick.

For example, in a PET center, a medical examination car, or a hospital, it is preferable to cover at least the accelerator or the raw fluorine parts with a lead shield having a plate thickness of 0.2 cm or more. Since 0.6 MeV protons are emitted from fluorine and the range in lead is 0.02 cm, the plate thickness is appropriate to more reliably shield this.

Next, a description will be given of management in which mutual consideration is given to the production amount, sales amount, elapsed time, receipt confirmation, etc. of the drug and nuclide. Based on the information requested by medical institutions, radioisotope generation time, synthesis time,
The production start time of the radioisotope is determined by back calculation based on the transport time and the like. By adjusting the concentration of the medium containing the radioisotope, such as the aqueous solution, based on the half-life of the radioisotope, the time required to transport the radioisotope to the site of the synthesizer, the synthesis time, and the time until administration to the patient after synthesis. Perform drug synthesis. Considering the predetermined synthesis time and the time until administration to the patient after the synthesis, an appropriate amount of drug can be administered to the patient when administering to the patient. In this way, this time management is algorithmized and a series of processes is controlled and controlled by a computer.
A drug manufacturing and sales system including a managing system is realized.

Next, various types of management based on half-life, particularly time management, will be described with reference to FIG. The radioisotope half-life t _h , the decay constant t _d = ln 2 / _{th h} , the amount of radioisotope required in the medical facility N (the amount of radioisotope to be administered varies depending on the weight of the subject, Taking this into consideration, the total amount of radioisotopes to be administered to a plurality of subjects), the amount generated by the particle generator N _0, and the yield of the synthesizer S, N = N ₀ S exp ( −t _d (t ₁ + t ₂ + t ₃ + t ₄ )). Here, t ₁ is the purification time of the nuclide (radioisotope) in the particle generator 35, and the obtained nuclide 13 reaches the synthesizers 4 and 21, while t ₂ is the transport 44 which reaches the synthesizers 4 and 21. It is the time required. t ₃ is the synthesis time in synthesizer 4 and 21, the agent 45 obtained in Synthesis device reaches the medical facility 46 (concept hospital including facility, a medical examination facilities). Here t ₄ is the transport time to be administered to a post-synthesis patient. The above equation represents how the nuclide (radioisotope) generated by the particle generator is attenuated from the amount N ₀ . The nuclide generation time t ₀ is determined by the balance between the nuclide generation rate G determined by the performance of the particle generator and the decay rate determined by the decay constant t _d of the nuclide attenuated during generation, and the quantity N ₀
Is generated, t ₀ that satisfies N ₀ = (G / t _d ) (1−exp (−t _d t ₀ )) is the generation time.

The system for controlling and managing the above-mentioned processes is provided with an information transmission system for checking whether or not each process is being processed as scheduled and, if there is a problem, dealing with the problem. And manage the entire process.

The algorithm is the same for each of the other supply methods. The difference is that each of the above times is different, so determine the start time of each process accordingly,
Perform process management. That is, the formula representing the manner of decay from _{N 0} can be modified as _{follows, N = N 0 Sexp (-t} d t 1) exp (-t d t 2) exp (-t d
t ₃ ) exp (−t _d t ₄ ) If the time taken before a certain process is different from the time determined by the algorithm for time management in advance, the current amount of nuclides and the time taken for subsequent processes , The time management is reconfigured, and the amount of nuclide administered to the human body is adjusted to an appropriate amount at the stage of drug synthesis or at the stage of administration. In this case, the time required for concentrating and diluting the amount of the nuclide is calculated in consideration of the algorithm.

It should be noted that nuclides (radioisotopes) are commonly used as described above.
Management and handling are common in terms of half-life and the handling of radiation, both for the management of medicines and the testing agents that use them.

Although the above mentioned 18F as a nuclide, there are other nuclides useful for cancer treatment and the like, and examples thereof are shown in Table 1. Table 1 lists production examples of the preparation for PET.

[0078]

[Table 1]

Next, examples of labeling compounds used for PET are described in Table 2.

[0080]

[Table 2]

Various examples of the PET business form will be described below. Prior to that, common matters will be outlined. First, the production of nuclides is mainly carried out by hospitals and laboratories (examination centers, etc.), nuclide manufacturers, and others (other than these). The production methods are, for example, cyclotrons and linacs. (Hereinafter sometimes referred to as a PET center), hospitals, medical examination centers, and other real estate facilities,
Vehicles are also possible, such as cars such as trailers and trains (including containers).

Next, regarding nuclide transport, hospitals, inspection laboratories (examination centers, etc.), nuclide manufacturers, and others (other than these) can be cited as main subjects. Transport vehicles include cars, trains (including containers), Helicopters, airplanes, two-wheeled vehicles, special-purpose aircraft, and the like. In addition, drugs (eg, FD
G) Synthetic, but the main subjects are hospitals, inspection organizations (examination centers, etc.), pharmaceutical companies, and others (other than these). On-column is suitable for the synthesis method, and manufacturing sites are hospitals, inspection centers such as examination centers, etc. Vehicles such as a PET center and a trailer and vehicles such as a train (including a container) are included.

The transport of drugs (for example, FDG) is mainly carried out by hospitals, inspection institutions (examination centers, etc.), pharmaceutical companies, and others (other than these). Transportation vehicles include cars and trains (containers). Including), helicopters,
Airplanes, motorcycles, special-purpose aircraft, and the like.

Further, the examination may be performed mainly by a hospital or an inspection institution (examination center, etc.) and others (other than these). Screening method is PET only (other than hospitals and testing institutions) or SP
ECT is available. Further, as the examination site, in addition to real estate facilities such as a PET center, a hospital, and an examination center, vehicles such as a car such as a trailer and a train (including a container) are possible.

In the present invention, a medical examination vehicle equipped with a medical examination device is also an example. In this case, it is particularly necessary to mount a particle generator such as a cyclotron and manufacture a medicine every time an examination is carried out in the vehicle. It is preferable to consider it. FIG. 6 shows an example of this examination car.

A power supply 48, a cyclotron 49, and a nuclide manufacturing apparatus 5 for PET are mounted on a large bus 47 such as an X-ray examination car.
1, a drug synthesis device 52, an inspection device 60, and the like are mounted. P
The nuclide manufacturing apparatus 51 for ET is an apparatus for making nuclides such as fluorine 18 by applying protons generated in the cyclotron 49 to water, and is integrated with the cyclotron 49 as a particle generator for generating and accelerating particles. Is configured. The size of the cyclotron 49 is about 2 m × 2 m. The power supply 48 is also set to such a size. Around the cyclotron 49, a lead plate for shielding protons is provided with a shield 50.
Deployed as. The nuclide produced by the nuclide producing apparatus 51 is synthesized by the synthesizing apparatus 52, and the medicine is taken out as a medicine outlet 55 as a medicine.
Remove from Reference numeral 53 denotes a control device, and reference numeral 54 denotes a control room. Those who wish to undergo a screening change their clothes in the changing room 56 and after administering the medicine, lie on the bed 59 and undergo a screening. The bed 59 is attached to the inspection device 60. still,
Reference numeral 58 is a chair, and reference numeral 57 is a driver's seat. For example, when it takes 2 hours to produce a PET nuclide and 2 hours to synthesize it, the PET examination car starts preparation for drug production by calculating backward from the examination time. If the power supply is large, the power supply will be taken from the grid at the place where the medical examination car is stopped. It is also conceivable to use a dedicated car equipped with a power supply together with the PET examination car.

Table 3 summarizes the PET nuclides.

The relationship between each nuclide and the half-life is shown.

[0089]

[Table 3]

Table 4 summarizes the gererator nuclides.

[0091]

[Table 4]

The production method of the daughter nuclei 68Ga, 62Cu, 82Rb from the parent nuclei 68Ga, 62Cu, 82Rb and the half-life of the daughter nuclei will be described.

(1) Examples of NaF NaF is one of the main radionuclei having properties that can be used for labeling bone tissue, and is used for evaluating metabolism of bone tissue, bone vasculature, bone marrow tumor and the like. By administering NaF, the distribution of radioactive material is shown in a photograph and can be used to examine the recovery status of a fractured bone.

(2) Examples of F ⁻ The synthesized drug means a compound containing F minus (F ⁻ ), and examples thereof include the compounds shown in Table 5.

[0095]

[Table 5]

¹⁸ F Production Method As the ¹⁸ F production method, H ₂ ¹⁸ O is irradiated with protons,
¹⁸ O (p, n) ¹⁸ is the production of F reaction with ¹⁸ F, the metal element to be mixed in the aqueous solution is removed by cation-exchange membrane, the addition of _K 2 CO ₃ solution in the aqueous ^{solution, 18} F Is eluted, and a solution containing ¹⁸ F anion is extracted with an anion exchange membrane. The remaining H _{2 1} ^{8 O} aqueous solution is returned to the aqueous solution of irradiating the original protons. The solution containing the extracted ¹⁸ F anion is subjected to a labeling treatment to become an ¹⁸ FDG drug. As described above, the extraction of ¹⁸ F is performed by combining the cation exchange membrane and the anion exchange membrane.

FIG. 7 shows an example of the time management system. The time management system is activated (S1), and based on the half-life of the target nuclide, the transport time 4 from the completion of the drug transport mode processing of the synthesized drug to the requested customer (delivery destination) is calculated (S1).
2). Considering nuclide attenuation between the transit time t _4, and, in consideration of the time for synthesizing the target drug amount and amount of attenuation between the target species, to calculate the nuclide content and time t ₃ required for drug synthesis . Further, the yield S at the time of synthesis of the target drug is calculated (S
3). Transport pathway nuclides, calculates the packaging and transport time _{t 2} (S4).

Based on the above t ₂ , t ₃ , t ₄ , yield S, and half-life of the target nuclide, the amount of nuclide required before the start of nuclide transport is determined in consideration of the decay during the production and purification of the nuclide. Calculate,
The time t ₀ required for the generation of nuclides required for this and the time t ₁ required for purification are calculated (S5). From the drug administration start time, a nuclide generation time, a nuclide transport time, a drug synthesis time, and a drug transport time are determined based on the above t ₁ , t ₂ , t ₃ , and t ₄ , and the nuclide amount in each process is determined. .

[0099] and amount N of as described above, a radioactive half-life t _{h isotopes,} when the decay constant and _{t d (= l n 2 /} t h), necessary for inspection radioisotopes (radionuclides), Between the amount N ₀ of the radioisotope generated by the particle generator, the purification time of the radioisotope is t ₁ , the transport time of the radioisotope to the synthesizer is t ₂ , the synthesis time is t ₃ , and the synthesis is the transport time to the human dose of the drug and a t _4, the yield of synthesized devices S
When, a relationship of _{N = N 0 Sexp (-t d} (t 1 + t 2 + t 3 + t 4)). In the synthesis of a nuclide, that is, a radioisotope, the synthesis is controlled by a time management process shown in FIG. For example, before entering the synthesis process, at least N
/ S) exp (+ t _d (t ₃ + t ₄ ))
Since t ₃ and t ₄ are clearly determined, the amount required for administration N
Is determined, and the equivalent drug amount at the time of nuclide generation and the drug amount at the time of synthesis are also determined from the drug amount at the time of administration that can be reliably delivered.

[0100] In FIG. 8, from the order information obtained from the customer, see _t h, _{t d} in the target species, found to N from the amount of the drug, use date and time, _t 1 from the place of _use, t _{2, t} 3, t
₄ changes.

Next, the aforementioned information is transmitted to each process. If an inconvenience occurs in each process up to the drug administration time, each step is reviewed and reconfigured.

FIG. 9 shows another example of the time management system.
This is basically the same as the example shown in FIG. 7, and the same steps are denoted by the same reference characters and description thereof will be omitted. In step S2 ', in addition to step S2, a yield S4 at the time of the drug transport mode processing is calculated. In step S4 ', in addition to step S4, a yield S2 at the time of nuclide packing is calculated. In the S5 'step, in addition to the S5 step, the yield 2 and the yield 4 are considered, and the yield S1 at the time of nuclide purification is also considered. In step S6 ', S
The nuclide amount in each process is determined in consideration of the yields S1, S2, S, and S4 in addition to the six steps.

FIG. 10 shows the drug synthesis process. In the figure, upon receiving information from the time management system, a required amount of a target compound as a drug raw material for producing a drug by synthesizing with a nuclide is prepared and set (S11). Based on the amount of nuclides transported, it is confirmed at the synthesis start time whether or not the nuclide concentration matches the information from the time management system (S12).
If the nuclide concentration does not match the information from the time management system, the nuclide concentration is adjusted by concentrating or diluting using physical properties such as the boiling point melting point (S13). From the synthesis start time based on the information from the time management system, the synthesis of the compound and the nuclide is started, and the required amount of the drug is synthesized (S14). After the completion of the synthesis of the target drug and its required amount, it is processed into a form that can be transported to the requesting customer (S
15). Drug administration is started (S16). It is confirmed that the drug has been delivered by the time of drug administration, and if there is any inconvenience, each step is checked (S17).

FIG. 11 shows a production flow of the positron-emitting drug. The manufacturing flow will be described with reference to a screen displayed on the system screen. 12 shows a medicine time management system screen, FIG. 13 shows a medicine order screen, FIG. 14 shows a process progress display screen, FIG. 15 shows a process progress (location) display screen, and FIG. FIG. 17 shows a process progress (use time) display screen, FIG. 18 shows a process progress (use amount) display screen, and FIG. 19 shows a delivery confirmation display screen. .

In FIG. 11, order information from the customer indicating the target nuclide, amount of drug, date and time of use, place of use, etc. is obtained (S21). The screen of the screen device initially displays the medicine order, medicine processing status confirmation, and delivery confirmation shown in FIG.

When the user clicks on a medicine order, a screen shown in FIG. 13 appears, and the order is made using this screen. A computer terminal equipped with this system on the customer side is connected to the time management system on the drug manufacturing side, and immediately starts processing after receiving an order. Both the customer and the manufacturing side can view the same screen at the same time on the screen of drug production and the like, and information is shared.

The medicine order can be received not only by this method but also by facsimile, telephone or the like. Even if the customer does not have the above-mentioned device, the medicine manufacturing side uses the time management system to perform the medicine order reception. Production control can be performed.

So far, the process starting from a drug order from a customer has been described. This can be used as a process to initiate a nuclide order from a customer and has that in mind. In the case of nuclide orders, it is assumed that management from a third organization is required in terms of radioactive material management. In FIG. 1, a third institution may be interposed between the nuclide or drug supply side and the customer. In this case, the basic information transmission process can be performed by the same process.

Next, the time management system is started, the transport route and transport time of the nuclide are calculated, and the time schedule until the use of the drug is determined (S22).

Based on the schedule, nuclide production starts,
It is generated (S23). Pack and transport the generated nuclides (S
24). The drug synthesis is started and manufactured (S25). The manufactured drug is transported (S26). Start drug administration (S
27).

The progress of the process can be checked on the display screen.

When the button for confirming the treatment status of the medicine in FIG. 12 is clicked, the medicine order screen shown in FIG. 13 and the screen shown in FIG. 14 are displayed, and the progress can be known. In the drawings, the medicine order may be a nuclide order, and the drug processing status confirmation may be a nuclide processing status confirmation.

When the user clicks on the place of use in FIG.
As shown in FIG. 5, a map appears, and a nuclide generation site, a synthesis site, a drug use site, their respective transport routes, and the current process being performed are displayed.

When the drug used in FIG. 14 is clicked, FIG.
As shown in FIG. 6, the name of the target nuclide, the name of the compound required for drug synthesis, and their amounts are displayed.

When the use time in FIG. 14 is clicked, FIG.
As shown in FIG. 7, the date, time,
The time of diagnosis, the amount of administration, etc. are displayed.

When the amount of use in FIG. 14 is clicked, FIG.
As shown in (1), the weight of each subject, the dose of the medicine, the diagnosis result (in some cases, only the customer side is displayed) and the like are displayed.

The chemicals shown in FIGS. 13 and 14 may be used as nuclides.

When the delivery confirmation is clicked in FIG. 12, FIG. 19 is displayed, and using this drawing, the target drug, the time when the target drug amount was delivered, and the like can be transmitted to the drug manufacturing side.

The drug manufacturer shown in FIG. 19 may be the nuclide manufacturer.

In FIG. 11, it is confirmed that the drug has been delivered by the time of drug administration, and if there is any inconvenience, it is checked (S2).
8) Return to step 22.

FIG. 20 shows an example of a pharmaceutical manufacturing and sales business.

A: In the PET center 101, nuclides are produced by the cyclotron 102, and a drug 104 is produced by the drug synthesizing apparatus 103. Drug 1 thus obtained
04 is transported by vehicle 105, and the nearby hospital facility 106,
107 (hereinafter referred to as a concept including a screening facility). In each hospital facility, an inspection device including positron emission type CT inspection equipment 108 and 109 is provided.

B: The nuclide 111 is manufactured by the cyclotron 110 at the PET center 121, and the nuclide 111 is manufactured at the PET center 122.
To 123 (possible to N places, not limited to two places)
A drug 114 is synthesized by 12 or 113 and supplied to nearby hospitals 116 and 117. Inspection equipment such as positron emission CT inspection equipment 118 and 119 is provided in each hospital. A vehicle 120 with radiation shielding means is used for transporting nuclides, and a vehicle 115 with radiation shielding means is similarly used for transporting drugs. In this example, nuclides such as 18F
Is manufactured in large quantities and supplied to multiple PET centers.
The centers (1) to (N) are equipped with a separation device for nuclides 18F,
It is used for synthesis after concentration.

C: In this example, nuclides or drugs are manufactured in a hospital, not in a PET center. That is, a drug manufacturing device such as a cyclotron 121 and a synthesis device 122 is installed in the hospital 120, and the drug 123 is supplied into the hospital. In this example, the medicine is not supplied outside the hospital. Reference numerals 124 and 12
Reference numeral 5 denotes a positron emission type CT inspection facility, the number of which is not limited.

D: In this example, protons are generated in the cyclotron 126 of the PET center 126, and the protons are exposed to water to produce nuclides 127.
And supplies it to the vehicle 128. In the vehicle 128, a drug synthesizing device 129 is provided.
Are combined and supplied to the hospitals 131, 132,...
Reference numerals 133, 134,... Denote positron emission type CT inspection equipment. In this case, it is possible to go to a hospital to manufacture a drug, so it is good to apply to a hospital without a drug manufacturing facility. Also, if drug production is started or completed before arriving at the hospital, it is suitable to cope with weight loss due to half-life. It is.

E: cyclotron 135, synthesizer 13
The drug 137 is synthesized in the vehicle 134 loaded with the vehicle 6. The vehicle goes to the hospitals 138, 139,..., For example, manufactures the drug 137 locally (on the hospital premises), and
39 ...). Reference numerals 140, 141, etc. denote positron emission type CT inspection equipment. In this case, it is possible to go to a hospital to manufacture a drug, so it is good to apply to a hospital without a drug manufacturing facility. Also, if drug production is started or completed before arriving at the hospital, it is suitable to cope with weight loss due to half-life. It is.

F: Hospital 1 equipped with cyclotron 143
The nuclide 143 is purchased from 42, the drug 147 is manufactured by the synthesizer 146 of the PET center 145, and the
9, 150... Reference numerals 151, 152, ... denote positron emission type CT inspection equipment. Reference numerals 144 and 148
Are transport vehicles.

G: The nuclide 154 is purchased from the hospital 153 having the cyclotron 154, and the vehicle 155 on which the synthesizer 156 is loaded goes to the hospital 158, 159. Code 16
Reference numerals 0, 162, etc. denote positron emission type CT inspection equipment. In this case, it is possible to go to a hospital to manufacture a drug, so it is good to apply to a hospital without a drug manufacturing facility. Also, if drug production is started or completed before arriving at the hospital, it is suitable to cope with weight loss due to half-life. It is.

H: PET equipped with cyclotron 163
The nuclide 164 is manufactured at the center 162,
8, 169... By a vehicle 165 or the like. In each hospital, inspection devices 170, 171... Are provided, respectively, and in addition, synthesis devices 166, 167. That is, a medicine synthesizing device is installed in the hospital, and the medicine is synthesized and supplied in the hospital.

I: Stacked vehicle 174 of cyclotron 172
Go to a hospital where nuclide 173 is manufactured. Hospital 1
Within each of 75, 176... Are inspection devices 179, 180. Therefore, each hospital is provided with a synthesizing device 177, 178,..., And the medicines are synthesized in the hospital and supplied to the examination.

It is needless to say that the above examples B to I can be combined as appropriate. For example, the correspondence between a hospital with a synthesis facility and a hospital without such a facility should be changed.

When supplying a radioisotope from a particle generation site to a plurality of synthesis sites and supplying a drug to a plurality of medical facilities, the reduction ratio of the radioisotope generated at the particle generation site can be easily controlled. For grasping, it is convenient to use a container with a timer. The radioisotope or drug is placed in a prescribed container that is in the form of a solution, and the transport / control container that contains the container contains, for example, (1) the type of radioisotope generated at the particle generation site; Time and elapsed time, (3) built-in microcomputer, function to calculate and display attenuation, (4) destination, (5) function to always identify position with built-in transmitter, etc. . The information is structured so that a system that controls and manages the series of processes can always grasp the information, and it is effective to manage the information using the system.

Drugs that have not been used for the convenience of the patient or the subject are put in the above-mentioned container and managed. It may be managed by a medical facility or a company that has a system that controls and manages the above series of processes. In the latter case, it is collected and stored in each container. After that, confirm that it has sufficiently attenuated (it is easy to confirm) and discard. Reuse container.

FIG. 21 shows an example of a nuclide production and / or sales business.

J: PET having cyclotron 182
The nuclide 183 is manufactured at the center 181 and supplied to nearby hospitals 185 and 186 by transportation means such as a vehicle 184. In each hospital, in addition to the inspection devices 187 and 188,
It is assumed that 89 and 190 are deployed.

K: The patient goes to the hospital with the cyclotron 191 loaded vehicle 193, manufactures the nuclide 192 locally, and supplies it to the hospital. Others are the same as the example of J.

L: A nuclide 196 is purchased from a facility such as a hospital 194 having a cyclotron 195, and a vehicle 197 is purchased.
And transport it to a nearby hospital. Others are the same as the example of J.

FIG. 22 illustrates an examination service business. In the screening service, a fee is collected as a screening fee.

M: A plurality of test devices 202 and 203 equipped with a drug manufacturing device (cyclotron 199, synthesizing device 200), a camera and the like are installed in a hospital 198, and a drug 201 is generated in the hospital to provide a screening service.

N: Synthesizer 21 in hospitals 208 and 209
Inspection devices 210, 21 equipped with cameras, etc.
1 is set up and a screening service is provided in the hospital. Nuclide 206
Is supplied from a PET center 205 having a cyclotron 205. Reference numeral 207 denotes a transport vehicle.

O: Synthesizing device 21 in hospitals 208 and 209
Inspection devices 210, 21 equipped with cameras, etc.
1 is provided, and a screening service is performed in the hospital, as in Example N. In this example, the nuclide 216 is a cyclotron 215
The patient goes to the hospital with the laminating vehicle 214, manufactures it locally, and provides it for inspection.

FIG. 23 exemplifies a business combining a medical examination service and the manufacture and sale of medicines as an example P. Drug manufacturing equipment (cyclotron 218, synthesis equipment 21) is installed in hospital 217.
9), a plurality of cameras (= inspection devices)
, 222, 223, 224...), And synthesizes the medicine 220 in the hospital to provide a screening service. In this example, the medicine 220 is supplied to the camera owned by the hospital, and is not supplied outside the hospital.

FIG. 24 shows an operation example of an examination center (hospital) as an example Q. That is, a screening center 225 provided with a cyclotron 226, a synthesizing device 227, one or a plurality of cameras 229, 230,... Is set up and operated including a drug 228 manufacturing process.

FIG. 25 shows an example of a medical examination car.

R: The examination car 231 is provided with a medicine manufacturing device (cyclotron 232, synthesizing device 233) and a camera (= inspection device) 235 so that the medicine 234 can be supplied in the car for the examination. This vehicle goes to a hospital facility 236, 237 (or an inspection facility; the same applies hereinafter), synthesizes the medicine 234, and performs a medical examination. Useful for hospital facilities without a drug synthesizer.

S: The nuclide 239 is manufactured at the PET center 238, and the patient goes out to the hospital facilities 236 and 237 by the examination car 240 loaded with the medicine synthesis device 241 and the camera 243, and
42 is synthesized and a medical examination is performed.

T: cyclotron 245 and synthesizer 24
6 is manufactured at a PET center 244 provided with 6 and goes to a hospital by a medical checkup car 247 loaded with a camera 249 to perform a medical checkup.

U: Cyclotron 251 and synthesizer 25
2 are manufactured at the PET center 250 with the medical equipment 2, and the medical examination vehicle 255 with the camera 256 is loaded on the hospital 237.
I go to the hospital and do a medical examination. In addition, the manufacturing agent is a transport vehicle 254.
And supply it to the hospital 257 where the inspection equipment is located.

[0149] These inspection vehicles are requested when the hospital has secured a certain number of inspection persons. The medical checkup car goes to the hospital where the request was made and carries out the medical checkup. Determine the hospital arrival time based on the number of medical examinations at the hospital, the time required to reach the hospital (calculated from the average hourly speed taking into account the distance and the time zone), and the time required for drug synthesis, and manufacture the medicine from the required amount of drug. Calculate the amount of nuclide to be done.

In the example of R, after arriving at the hospital, production of nuclides using a cyclotron is started, and after the synthesis of the drug is completed, administration is performed to the examiner to perform an examination. In the example of S, after loading nuclides manufactured in another facility in a medical checkup car,
Head to the hospital and synthesize the drug after arriving at the hospital. After that, it is the same as No. 18. In the example of T, the medicine synthesized in another facility is loaded on a medical examination car, and then the patient goes to the hospital. Immediately after arriving at the hospital, conduct a medical checkup. In the example of U, only the camera is loaded on the medical checkup car, the medicine is synthesized at another facility,
Transported separately by another transport medium.

In FIG. 1, when the nuclide manufacturer and the drug manufacturer are different, the nuclide manufacturer displays an order containing at least four pieces of information on the date and time of use, the place of use, the amount of use, and the target nuclide with respect to the positron-emitting drug. Screen display device 9 to be displayed
A statistical processing device for performing a statistical process 92 based on information for inputting and statistically inputting a shipping amount of a drug synthesized using a nuclide manufactured based on the half-life of the nuclide; and By providing a billing processing device that performs a billing process 93 for billing for the amount of medicines shipped, nuclides can be sold by making a bill for the amount of medicines shipped.

The drug manufacturer accepts an order containing at least four pieces of information on the date and time of use, the place of use, the amount of use, and the target drug with respect to the positron emission type drug for each order, and displays the order display screen 91 '. A statistical processor 92 'for performing statistical processing 92' for statistically calculating the shipping amount of a drug synthesized using the nuclide manufactured based on the half-life of the nuclide for each order; (Delivery destination) By providing a billing processing device that performs billing processing 93 'for each drug delivery amount, it is possible to sell the synthesized medicine by performing billing processing for each delivery destination.

Therefore, on the screen of the screen display device 91, 1) delivery destination, 2) date of delivery, 3) drug name or nuclide name, 4) drug quantity or nuclide quantity, 5) delivery form described above In addition, the contents of the billing process for each delivery destination for the drug delivery amount are displayed, and the displayed contents are output to the terminals 71 and 72 by the communication means 74 together with printing.

FIG. 13 is a conceptual diagram of a nuclide production vehicle for PET used in one example of the present invention. The reference numerals in common with the embodiment of FIG. 6 are the same. In particular, in this case, a nuclide is manufactured by mounting a particle generator such as a cyclotron, and drug synthesis is not performed.

A large-sized bus 258 such as an X-ray examination car has a power supply 48, a cyclotron 49, and a nuclide production apparatus 5 for PET.
1, a nuclide packing device 259, a nuclide takeout port 260, etc. are mounted. The PET nuclide manufacturing apparatus 51 is an apparatus for making nuclides such as fluorine 18 by applying protons generated by the cyclotron 49 to water, and is integrated with the cyclotron 49 as a particle generator for generating and accelerating particles. Is configured. The size of the cyclotron 49 is about 2 m × 2 m. The power supply 48 is preferably as large as that. A lead plate for shielding protons is provided as a shield 50 around the cyclotron 49. The nuclide produced by the nuclide production apparatus 51 is packed by the packing apparatus 259 and taken out from the nuclide takeout port 260. Reference numeral 53 denotes a control device, reference numeral 54 denotes a control room, reference numeral 78 denotes a chair, and reference numeral 57 denotes a driver's seat. For example, assuming that the production of the nuclide for PET is 2 hours, the calculation is performed backward from the examination time, and the production of the nuclide is started in consideration of the synthesis time of the drug production. If the power supply is large, the power supply will be taken from the grid at the place where the PET nuclide manufacturer is stopped.

FIG. 27 shows a conceptual diagram of a PET drug manufacturing vehicle used as an example of the present invention. 6 and 26 have the same reference numerals. In this case, in particular, a nuclide is manufactured by mounting a particle generator such as a cyclotron, and thereafter, a drug is manufactured during transportation or upon arrival at a hospital facility or the like.

A large-sized bus 261 such as an X-ray examination car has a power supply 48, a cyclotron 49, and a nuclide production apparatus 5 for PET.
1, a drug synthesizing device 52, a drug packing device 262, a drug outlet 55 and the like. The PET nuclide manufacturing apparatus 51 applies protons generated by the cyclotron 49 to water to apply
This is a device for producing nuclides such as 8, and is integrated with a cyclotron 49 as a particle generator for generating and accelerating particles to constitute a nuclide production device. The size of the cyclotron 49 is about 2 m × 2 m. The size of the power supply 48 is preferable. A lead plate for shielding protons is provided as a shield 50 around the cyclotron 49. The nuclide produced by the nuclide producing apparatus 51 is synthesized by the synthesizer 52, packed in the packing apparatus 262, and taken out from the medicine outlet 55. Reference numeral 53 denotes a control device, and similarly, reference numeral 54 denotes a control device.
Is a control room, 78 is a chair, and 57 is a driver's seat.
For example, assuming that it takes 2 hours to manufacture a PET nuclide and 2 hours to synthesize a drug, the PET drug synthesis vehicle starts calculating nuclides by calculating backward from the examination time. If the power supply is large, P
At the place where the ET nuclide manufacturer is stopped, power will be taken from the grid.

As described above, according to the embodiment of the present invention, the amount of radioactivity in each process can be grasped, the time from the synthesis of a drug to the administration to a human body can be shortened, the time can be easily managed, and the administration can be performed at the time of synthesis. Because it is possible to predict the amount and synthesize the drug,
In addition, the work performed by the physician at the time of administration, such as checking the dose and adjusting the amount of the drug, is reduced, and the probability of erroneous administration is reduced, which has the effect of improving the reliability of the diagnostic technique. Since the amount of radioactivity in the entire process up to the subsequent disposal can be ascertained, the amount of waste generated of nuclides can be reduced comprehensively, and scattering, erroneous delivery, erroneous disposal, etc. of radioactive materials can be reduced, and safety in radioactivity management can be reduced. The effect is that the quality of management is improved.

[0159]

According to the present invention, it is possible to use a drug efficiently in terms of the production amount or the dose amount even in a medical examination using a radionuclide with a short half-life.

[Brief description of the drawings]

FIG. 1 is a system diagram showing an embodiment of the present invention.

FIG. 2 is an explanatory diagram showing a schematic example of a flow of manufacturing or using a medicine.

FIG. 3 is an explanatory diagram showing a schematic example of a flow of manufacturing or using a medicine.

FIG. 4 is an explanatory diagram of the PET principle.

FIG. 5 is an explanatory diagram illustrating a time relationship according to a typical example of the present invention.

FIG. 6 is an explanatory diagram showing an in-vehicle layout of a medical examination car according to an embodiment of the present invention.

FIG. 7 is a time management system diagram.

FIG. 8 is a time management process diagram.

FIG. 9 is a time management system diagram.

FIG. 10 is a drug synthesis process diagram.

FIG. 11 is a production flowchart of a positron-emitting drug.

FIG. 12 is a screen view of a medicine time management system.

FIG. 13 is a diagram of a medicine order screen.

FIG. 14 is a view of a process progress display screen.

FIG. 15 is a view showing a process progress status (location) display screen.

FIG. 16 is a view showing a process progress status (used nuclide) display screen.

FIG. 17 is a view showing a process progress status (use time) display screen.

FIG. 18 is a view showing a process progress status (usage amount) display screen.

FIG. 19 is a delivery confirmation display screen view.

FIG. 20 is an illustration of a drug production and sales business.

FIG. 21 is an illustration of a nuclide manufacturing business.

FIG. 22 is an illustration of an examination service business.

FIG. 23 is an explanatory diagram showing an example of merging a medical examination service business and a drug manufacturing business.

FIG. 24 is an explanatory diagram for explaining the operation of the examination center.

FIG. 25 is an exemplary view of a medical examination car.

FIG. 26 is an explanatory view showing an in-vehicle layout of a nuclide production vehicle for PET according to an embodiment of the present invention.

FIG. 27 is an explanatory diagram showing an in-vehicle layout of a PET drug manufacturing vehicle according to an embodiment of the present invention.

[Explanation of symbols]

1,14,25,28 ... hospital facility, 2,20 ... cyclotron, 3,4,21,26,27,30 ... synthesizer,
5 ... inspection device, 11 ... screening service, 13 ... nuclide, 19
... Nuclide manufacturing facility.

 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Akira Uemura 3-1-1 Sachimachi, Hitachi-shi, Ibaraki Pref. Nuclear Power Division, Hitachi, Ltd. (72) Junichi Hirota 3-1-1 Sachimachi, Hitachi-shi, Ibaraki No. 1 Hitachi, Ltd. Nuclear Power Division (72) Inventor Naoyuki Yamada 7-2-1, Omika-cho, Hitachi City, Ibaraki Pref. Hitachi, Ltd. Power and Electricity Development Laboratory (72) Inventor Akio Motochi Tokyo 4-6-6 Kanda Surugadai, Chiyoda-ku Hitachi, Ltd. (72) Inventor Kazuo Hiramoto 7-2-1, Omika-cho, Hitachi City, Ibaraki Pref. Hitachi, Ltd. Power and Electricity Development Laboratory (72) Inventor Umegaki Kikuo 7-2-1, Omika-cho, Hitachi City, Ibaraki Pref. Hitachi, Ltd. Power and Electricity Development Laboratory (72) Inventor Inoue Husband 2-51-11, Harita-cho, Hachioji-shi, Tokyo (72) Inventor Setsu Kotsuki 4-1-21-2, Nishihara, Kashiwa-shi, Chiba (72) Inventor Masaaki Kobayashi 631-12, Ishikawa, Sakura-shi, Chiba (72) Invention Person Shuzaburo Suzuki 4-7-3 Asahigaoka, Yokkaido, Tokyo Metropolitan City 17-11 No. 302 (72) Inventor Katsumi Mori 4808-89 F-term (reference) 4C085 HH03 KA29 KB07 KB20 4G075 AA03 AA23 AA39 AA62 AA65 BA02 BA10 CA38 4H006 AA05 AB20 AC84 AC90

Claims (21)

[Claims] 1. A method of manufacturing a positron-emitting drug, comprising: receiving an order attached to at least four pieces of information on a positron-emitting drug, such as date and time of use, place of use, amount of use, and target nuclide; The process time including the transport time of the nuclide, the start time of drug synthesis by the nuclide, and the transport time of the drug is calculated based on the half-life of the nuclide, and a time schedule is created based on the calculated half-life. A method for producing a positron emitting drug. 2. A method for producing a positron-emitting drug, wherein a process time including a nuclide generation start time and a drug synthesis start time by the nuclide is calculated based on the half-life of the nuclide, and a preparation state for examination is referred to. And instructing the generation of the nuclide. 3. A method for producing a positron-emitting drug, comprising: receiving an order with at least four pieces of information about a positron-emitting drug, such as date and time of use, place of use, amount of use, and target nuclide; Calculating the process time including the transport time of the nuclide, the start time of drug synthesis by the nuclide, and the transport time of the drug based on the half-life of the nuclide, and instructing the generation of the nuclide by referring to the preparation status of the screening A method for producing a positron-emitting drug. 4. The preparation time for a medical examination according to claim 3, wherein the process time including the order, the nuclide generation start time, the nuclide transport time, the drug synthesis start time by the nuclide, and the drug transport time is displayed. A method for producing a positron-emitting drug, characterized by displaying the same on the same screen and instructing generation of the nuclide through the screen. The manufacturing method of claim 5] positron-drug, the half-life of the nuclide _{t h,} the decay constants _t d _{(= l} n 2 /
t _h ), N is the amount of nuclide used for inspection, No is the amount of nuclide generated by the particle generator (cyclotron), t _{1 is} the nuclide purification time, t _{2 is} the nuclide transport time, The production time is t ₃ , and the time required to test the drug is t.
_4, and the yield of the drug production is S, and the production of the nuclide is based on the half-life of the nuclide so that N = No · S exp (−t _d (t ₁ + t ₂ + t ₃ + t ₄ )). A method for producing a positron-emitting drug. 6. A method for supplying a positron-emitting drug, comprising: receiving an order with at least four pieces of information on a positron-emitting drug, such as date and time of use, place of use, amount of use, and target nuclide; The process time including the transport time of the nuclide, the start time of drug synthesis by the nuclide, and the transport time of the drug is calculated based on the half-life of the nuclide, and the synthesis of the drug and the supply route of the drug are included based on the calculated half-life. A method for supplying a positron-emitting drug, comprising creating a time schedule for supplying the drug. 7. The method for supplying a positron-emitting drug according to claim 6, wherein clinical data as a result of using the supplied drug is stored in association with the nuclide. 8. When supplying a nuclide for a positron-emitting drug, the nuclide receives an order based on at least four pieces of information on the purpose of use, place of use, amount used, and target nuclide, and halves the information and nuclide. A method for supplying a positron-emitting drug nuclide, characterized in that the nuclide generated based on the period is supplied to an ordering side. 9. The method according to claim 8, wherein the ordering side is a hospital facility or a testing facility. 10. The method for supplying a positron-emitting nuclide for a drug according to claim 8, wherein the order and / or the supply are performed through a management organization which manages a radioactive substance. 11. When supplying a nuclide for a positron-emitting drug, the nuclide receives an order based on at least four pieces of information on the purpose of use, place of use, amount used, and target nuclide, and halves the information and the nuclide. The nuclide generated based on the period is supplied to the hospital facility or laboratory on the ordering side, the transport time is calculated from the transport route and transport means between the nuclide generation facility and the hospital facility or laboratory on the ordering side, and the transport time of the target nuclide is calculated. A method for supplying a nuclide for a positron-emitting drug, comprising: starting generation and supplying a nuclide in an amount corresponding to an order amount of the ordering facility. 12. A positron-emitting drug manufacturing and processing apparatus, comprising: a screen display device for receiving at least four pieces of information about a positron-emitting drug, such as date and time of use, place of use, amount of use, and target nuclide; A processing device for calculating a time, a transport time of the nuclide, a start time of drug synthesis by the nuclide, and a process time including a transport time of the drug based on a half-life of the nuclide, and creating a time schedule based on the half-life; A manufacturing and processing apparatus for a positron-emitting drug, comprising: 13. A sales processing device for a positron-emitting drug, comprising: a screen display device for displaying an order of a positron-emitting drug containing at least four pieces of information on date and time of use, place of use, amount of use, and target nuclide; A statistical processing device for inputting and statistically the shipping amount of a drug synthesized using the nuclide manufactured based on the half-life of the nuclide, and a claim processing device for billing the drug shipping amount based on the statistic. A positron-emitting drug sales processing device characterized by having: 14. A sales processing device for a positron-emitting drug, wherein an order containing at least four pieces of information on a positron-emitting drug, such as date and time of use, place of use, amount of use, and target drug, is received for each order and displayed on an order screen. A screen display device, a statistical processing device that stats, for each order, a delivery amount of a drug synthesized using a nuclide manufactured based on the half-life of the nuclide, and a drug delivery device for each orderer based on the statistic. A positron-emitting drug sales processing device, comprising: a billing device for making a bill for a height. 15. An apparatus for manufacturing and processing a positron-emitting drug, wherein at least four pieces of information regarding the positron-emitting drug, such as date and time of use, place of use, amount of use, and target nuclide, are received and displayed on a screen, and the preparation status of a medical examination is displayed. A screen display device for displaying a screen, and a process time including a generation start time of the nuclide, a transportation time of the nuclide, a start time of drug synthesis by the nuclide, and a transportation time of the drug, are calculated based on a half-life of the nuclide, A positron-emitting drug production processing device, comprising: a processing device for creating a time schedule based on the time schedule and referring to the preparation status of the medical examination to instruct generation of the nuclide. 16. A system for producing a positron-emitting drug, wherein at least four pieces of information on the positron-emitting drug, such as date and time of use, place of use, amount of use, and target nuclide, are received and displayed on the screen, and the preparation status of the examination is displayed on the screen. A screen display device to be displayed and a process time including a generation start time of the nuclide, a transport time of the nuclide, a start time of drug synthesis by the nuclide, and a transport time of the drug are calculated based on the half-life of the nuclide. A processing device that creates a time schedule based on the above, and instructs the generation of the nuclide by referring to the preparation status of the screening, a device that generates a positron emitting nuclide according to the time schedule, and a second device that transports the nuclide A transport device, a drug synthesis device that synthesizes a drug using the nuclide as a raw material, a second transport device that transports the drug, and a confirmation signal of the drug delivery to the processing device. A system for producing a positron emitting drug, comprising: a transmitting system for transmitting. 17. An image processing apparatus using a nuclide, a reception processing apparatus for registering an order of an inspection chemical synthesized from the nuclide and an examination time, a nuclide depending on a half-life of the nuclide, and a positron from the nuclide. A drug production instruction device for instructing a timing of synthesizing a release type inspection drug, a request processing device for responding to an order for the synthesized inspection drug, and performing a delivery process and a request process for the inspection drug; Image processing device. 18. An image processing apparatus using a nuclide, wherein a memory for storing the examination item of the examiner and the examination item of the examiner, a name of the examiner, and a preparation state for the examination are displayed on a screen, and the half life of the nuclide depends on the half life. An image processing apparatus comprising: a drug production instruction device for producing a nuclide and instructing a timing of synthesizing a test agent from the nuclide. 19. An image processing apparatus using a nuclide, wherein an examiner and a test item of a tumor for the examiner are stored, and when the test agent is synthesized from the nuclide, the test agent is administered from the synthesis. A storage device for storing the time required until, a screen display of the name of the examiner and the status of the examination preparation, and displaying the time, depending on the half-life of the nuclide,
An image processing apparatus, comprising: a drug production instruction device for producing a nuclide and instructing a timing of synthesizing a test drug from the nuclide. 20. An image processing apparatus using a nuclide, wherein a positron emission type CT examination equipment is provided in a medical examination car, and a storage device for storing an examiner and an examination item of a tumor for the examiner, and depending on a half-life of the nuclide. A synthesizing instruction device for instructing the synthesis of a positron emission-type test drug from a nuclide, and a registration device for registering a test result of the test drug administered to the examiner in connection with the test drug. An image processing apparatus characterized by the above-mentioned. 21. An image processing apparatus using a nuclide, a synthesis instructing device for displaying a screening preparation status of the examiner on a screen and instructing to synthesize a test drug from the nuclide, and a synthesized test drug to a transport route. An image processing apparatus, comprising: a use device to be put on a laboratory for use; and a storage device for storing clinical data as a result of use in association with a nuclide.